Investment Rating - The report maintains a "Buy" rating for the company [5][11]. Core Views - The company has shown steady performance in the first half of 2025, with a focus on developing cycloidal reducers and collaborating with various companies in fields such as humanoid robots, robotic dogs, exoskeletons, and dexterous hands [2][11]. - The target price is set at 23.64 CNY, reflecting a 47 times PE ratio for 2025, based on the company's robust earnings forecast [11]. Financial Summary - Total revenue is projected to grow from 1,946 million CNY in 2023 to 4,201 million CNY by 2027, with a compound annual growth rate (CAGR) of approximately 19.2% [4][12]. - Net profit attributable to shareholders is expected to increase from 182 million CNY in 2023 to 669 million CNY in 2027, with significant growth rates, particularly a 76.9% increase in 2024 [4][12]. - Earnings per share (EPS) is forecasted to rise from 0.21 CNY in 2023 to 0.78 CNY in 2027 [4][12]. Market Data - The company's market capitalization is approximately 14,996 million CNY, with a current share price of 17.44 CNY [6][5]. - The stock has shown a 52-week price range of 6.92 CNY to 19.00 CNY, indicating significant volatility and potential for growth [6]. Industry Position - The company is positioned in the transportation equipment and consumer discretionary sectors, with a focus on high-precision planetary and cycloidal reducers [5][11]. - The automotive and aerospace sectors are identified as key growth areas, with ongoing projects with major industry players [11].
豪能股份(603809):中报业绩稳健,积极布局减速器产能